150 related articles for article (PubMed ID: 16076907)
1. Antipsychotic dose-sparing effect with addition of memantine.
Sleeper RB
Ann Pharmacother; 2005 Sep; 39(9):1573-6. PubMed ID: 16076907
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
Onor ML; Saina M; Trevisiol M; Cristante T; Aguglia E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):205-9. PubMed ID: 17020789
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Beier MT
Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
[TBL] [Abstract][Full Text] [Related]
4. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions.
Ballard C; Corbett A; Chitramohan R; Aarsland D
Curr Opin Psychiatry; 2009 Nov; 22(6):532-40. PubMed ID: 19696673
[TBL] [Abstract][Full Text] [Related]
5. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
Grossberg GT; Pejović V; Miller ML; Graham SM
Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
[TBL] [Abstract][Full Text] [Related]
6. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
Gauthier S; Loft H; Cummings J
Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
[TBL] [Abstract][Full Text] [Related]
7. Clock drawing and frontal lobe behavioral effects of memantine in Alzheimer's disease: a rater-blinded study.
Paskavitz JF; Gunstad JJ; Samuel JE
Am J Alzheimers Dis Other Demen; 2006 Dec-2007 Jan; 21(6):454-9. PubMed ID: 17267379
[TBL] [Abstract][Full Text] [Related]
8. Risperidone and dementia-related aggression: new indication. A last resort, no better than haloperidol.
Prescrire Int; 2009 Dec; 18(104):248. PubMed ID: 20025088
[TBL] [Abstract][Full Text] [Related]
9. Memantine for behavioral disturbances in frontotemporal dementia: a case series.
Swanberg MM
Alzheimer Dis Assoc Disord; 2007; 21(2):164-6. PubMed ID: 17545743
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database.
Vidal JS; Lacombe JM; Dartigues JF; Pasquier F; Robert P; Tzourio C; Alpérovitch A
Neuroepidemiology; 2008; 31(3):193-200. PubMed ID: 18815451
[TBL] [Abstract][Full Text] [Related]
11. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
Feldman HH; Schmitt FA; Olin JT;
Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
Jönsson L
Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
[TBL] [Abstract][Full Text] [Related]
13. Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease.
Meguro K; Meguro M; Tanaka Y; Akanuma K; Yamaguchi K; Itoh M
J Geriatr Psychiatry Neurol; 2004 Jun; 17(2):61-7. PubMed ID: 15157345
[TBL] [Abstract][Full Text] [Related]
14. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological treatment of dementia.
Schwarz S; Froelich L; Burns A
Curr Opin Psychiatry; 2012 Nov; 25(6):542-50. PubMed ID: 22992546
[TBL] [Abstract][Full Text] [Related]
17. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
[TBL] [Abstract][Full Text] [Related]
18. [Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)].
Agüera-Ortiz LF;
Rev Neurol; 2010 Nov; 51(9):525-34. PubMed ID: 20979032
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of memantine in the treatment of Alzheimer's disease].
Molinuevo Guix JL; Lladó Plarrumaní A
Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
[TBL] [Abstract][Full Text] [Related]
20. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
